Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Pathology|January 1, 1987
A second Australian family with hemoglobin North Shore (beta 134 Val----Glu)H Gurney, I Baig, S Gordon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2011
Metformin in prostate cancer: two for the price of oneA Clements, B Gao, S H O Yeap, et al.
British Journal of Cancer|August 17, 2000
A phase II trial of paclitaxel and epirubicin in advanced breast cancerD Rischin, J Smith, M Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factorH Gurney, H Anderson, J Radford, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2006
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerN A Spry, L Kristjanson, B Hooton, et al.
Internal Medicine Journal|June 16, 2016
The effect of pulmonary function testing on bleomycin dosing in germ cell tumoursF T Roncolato, M Chatfield, B Houghton, et al.
Blood|September 15, 1992
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialR Pettengell, H Gurney, J A Radford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1990
Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinomaH Gurney, D Crowther, H Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
Seminars in Oncology|November 28, 1997
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New ZealandJ F Bishop, J Dewar, G Toner, et al.
Pageof 6